newsfilter
← Latest News
GlobeNewswire·

Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Identified important optimization features for its platform to mitigate PFO risks in current and future programs Advanced iPS cell differentiation protocol for the diabetes program in preparation for anticipated